Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase EARLY_PHASE1 3Phase 2 2Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Melanoma 2Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paget's Disease, Mammary 1Nasopharyngeal Carcinoma 1Malnutrition 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Docosahexaenoic Acids × Clear all
NCT03831178 2025-06-26

DHA-WIN

AHS Cancer Control Alberta

Phase 2 Active not recruiting
76 enrolled
Breast

Breast Neoplasms

NCT01849250 2021-12-28

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

National Cancer Institute (NCI)

Phase 2 Completed
65 enrolled 11 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Paget's Disease, Mammary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡